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The mechanism whereby endothelin stimulates motogenesis of vascular smooth muscle cells is not understood. Here we show that endothelin-1 
stimulates phospholipase D by a protein kinase C and tyrosine kinase dependent mechanism, and present evidence that implicate the phosphatidic 
acid formed by phospholipase D in the mitogenic response. 
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1. INTRODUCTION 
Endothelin-1 (ET-l) is known to be mitogenic for 
vascular smooth muscle cells [ 1,2] and fibroblasts [3-51 
maintained in culture. This mitogenic activity has been 
associated with the stimulated expression of the proto- 
oncogenes c-fis and c-myc in both smooth muscle cells 
[2] and fibroblasts [4]. ET-l acting at ET, receptors is 
known to stimulate both phospholipase C (PLC) [3,4] 
and phospholipase D (PLD) [5] in vascular smooth 
muscle cells. Phosphatidic acid is the primary lipid 
product of PLD, and it (or its lyso derivative) may be 
mitogenic in its own right [6,7]. Phospholipase D has 
been reported as being activated in several ways, includ- 
ing stimulation by protein kinase C (PKC) (e.g. [8-131) 
and elevation of intracellular free Ca” (e.g. [10,14]). 
Two recent reports suggest he possibility that tyro- 
sine kinases may be involved in the mitogenic response. 
Firstly, it was demonstrated that ET-l, along with vaso- 
pressin and angiotensin II, enhance tyrosine phospho- 
rylation in glomerular mesangial cells [15]. These ag- 
onists all share the PLC receptor-effecter mechanism. 
It was also shown that fMet-Leu-Phe acting on neutro- 
phils activates PLD by a mechanism involving en- 
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hanced protein tyrosine phosphorylation [16]. This ag- 
onist, which stimulates PLC, has previously been re- 
ported to activate tyrosine phosphorylation by an unre- 
solved mechanism. Following from this, it has recently 
been shown that pervanadate induced enhancement of 
tyrosine phosphorylation leads to PLD activation in 
neutrophils [17]. 
In view of these various reports, we set out to study 
the mechanism by which ET-l regulates PLD in cul- 
tured vascular smooth muscle cells. We provide evi- 
dence that both PKC and tyrosine kinases are involved 
and ask whether this activation of PLD could be instru- 
mental in mediating endothelin stimulated mitogenesis. 
2. EXPERIMENTAL 
A10 cells were maintained as previously described [3], were seeded 
into 24-well multiwell plates and grown to confluence. Experiments 
were performed in a balanced salt solution consisting of (mM) NaCl 
120, KC1 5.4, NaHCO, 16.2, MgSO, 0.8, NaH,PO, 1, CaCI, 1.8, 
o-glucose 5.5, 4-(2-hydroxethyl)-1-piperazine ethane sulphonic acid 
30, at pH 7.4. 
The procedure for labelling of Al0 cells with ‘*P and analysis of 
phospholipids was as described previously for endothelial cells [16]. 
Briefly, monolayer cultures of Al0 cells were loaded with 32Pi at a 
concentration of 0.25 MBq/ml in a 0.4 ml phosphate-free balanced salt 
solution for 24 h. In order to study PLD the generation of [“PIPBut 
(phosphatidylbutanol) was measured: this is generated in the presence 
of butanol by the transphosphatidylation reaction unique to PLD. 
Cells were exposed to 50 mM butanol for 10 min prior to, and during, 
experimentation. We have fully characterised this procedure lsewhere 
[13], and shown that 50 mM butanol converts all the PLD product to 
PBut, so that residual agonist stimulated [“*PIPA is a product of the 
PLC/diacylglycerol kinase route. Where PKC activating phorbol 
myristate acetate (PMA), PKC inhibitor Ro 31-8220 (a kind gift of 
Roche Products Ltd., Welwyn, UK)/or tyrosine kinase inhibitor ST 
271 [16] (a kind gift of Wellcome Foundation Ltd., Beckenham, UK) 
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were used they were included for 10 or 20 min prior to and during the 
3 min incubation. The reaction was terminated with methanol, lipids 
were extracted with chloroform and separated on oxalatecoated 
Whatman silica gel 60A thin layer chromatography plates in ethylace- 
tate/acetic acidkimethylpentane (9:2:5). 
Assay of inositol phospholipid PLC in [3H]inositol loaded A10 cells 
by formation of total [‘Hlinositol (poly)phosphates in the presence of 
10 mM lithium was as described previously [3]. 
For determination of [‘Hlthymidine incorporation into nucleic acid, 
cells were maintained serum-free for 24 h, followed by stimulation 
with 1 PM insulin f ET-1 for 24 h. During the last 4 h, [‘H]thyrnidine 
was added to 1 ,&i/ml, following which the cells were washed sequen- 
tially in 5% trichloroacetic acid, ethanol, and solubilised and counted 
in 0.1 M NaOH. Statistical analysis was on log transformed ata to 
correct for unequal variance: one way analysis of variance was fol- 
lowed by Duncan’s multiple range test at significances of 0.05 and 
0.01. The values for IC,, were determined by GraphPad. 
3. RESULTS 
3.1. Stimulation of PLD 
Table I shows the accumulation of [32P]PA and 
[32P]PBut in response to 100 nM ET-l in the presence 
of 50 mM butanol. These results show the stimulated 
accumulation of [32P]PBut, clearly demonstrating stim- 
ulation of PLD by ET-1 in these cells. Further studies 
on stimulation by ET-l of [32P]PBut showed a response 
reaching a maximum at 3 min and with an EC,, of 
about 3 nM (data not shown). PMA also elevated 
[32P]PBut accumulation in these cells, with little or no 
elevation of [32P]PA (Tables I and II). PKC inhibitor Ro 
31-8220 (compound 3 in [18]) inhibited agonist stimu- 
lated [32P]PBut (Table I) with no effect on unstimulated 
cells. 
To investigate a possible role for tyrosine kinase in 
the ET-l stimulated events we used a potent and selec- 
tive tyrosine kinase inhibitor ST 271 [16]. Table II 
shows that 100 ,uM ST271 had no effect on [32P]PA 
accumulation in control and stimulated (ET- 1 or PMA) 
cells. However, ST 271 (100 PM) caused a substantial 
reduction in the ET-l stimulated [32P]PBut (over four 
separate, experiments the reduction by ST271 was to 
22%, P c 0.05 by paired Student’s t-test) with only a 
minor reduction in the PMA stimulated [32P]PBut. It 
Table I 
Accumulation of [32P]PA and [32P]PBut: effect of PKC stimulation and 
inhibition 
[32P]PA [=P]PBut 
Control 189 f 21 315f 63 
ET-l 726 f 242 1791 f 63 
ET-l + Ro 318220 1243 f 120* 769 k 9* 
PMA 334 f 47 2143 f 351 
PMA + Ro 31-8220 378 f 34 443+ 82 
ET-l was at 100 nM, Ro 31-8220 at 10pM and PMA at 100 nM. Data 
are cpm, mean f S.E.M. (n = 9) from 3 separate xperiments each in 
triplicate. Significantly different from ET-1 alone, *P < 0.01. 
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Fig. 1. Effect of ST 271 on stimulation of [“PIPBut accumulation in 
A10 cells by 50 nM ET-l (open circles) and 100 nM PMA (closed 
circles). Stimulation was for 3 min in the presence of 50 mM butanol. 
Data are normalised to 100% of response (stimulated minus basal) to 
either ET-l or PMA in the absence of ST 271 and pooled across four 
separate xperiments each in triplicate. 
can be seen from Fig. 1 that ST 27 1 had an I&, of about 
3 ,uM when stimulation was with ET-l, while the IC,, 
was greater than 100 ,uM when stimulation was with 
PMA. At lOpM, ST 271 inhibited the response to ET-l 
by about 70% while the response to PMA was unaf- 
fected. 
Further experiments were designed to assess the effect 
of ST 271 on related activities; e.g. in the range 0.1-100 
,uM there was no effect on stimulation of total [3H]inos- 
itol (poly)phosphates in [3H]inositol abelled cells [3] by 
100 nM ET-l. Furthermore 100 ,uM ST 271 had no 
effect on the augmentation by Ro 31-8220 of this ET-l 
stimulated PLC response. 
3.2. Stimulation of [3H]thymidine incorporation 
Using [3H]thymidine incorporation as an index of 
mitogenesis in cultured A10 cells maintained serum-free 
for 24 h prior to stimulation, we found only an unrelia- 
ble stimulation with 24 h ET-l alone (up to 100 nM) 
but a reproducible stimulation in the presence of insulin. 
In a typical experiment [3H]thymidine incorporation 
per well (dpm x 10e3,X f S.E.M., n = 3) was: control, 
Table II 
Effect of ST 271 on stimulated [32P]PA and [‘*PIPBut accumulation 
[=P]PA [3ZP]PBut 
Control ST 271 Control ST 271 
Control 460 f 41 423 f 54 568 + 32 579+ 3 
ET-l 732 f 165 770 f 205 1413 f 249 768 _+ 136* 
PMA 359 + 79 351 f 60 1859 f349 1204It 93 
ET-l was at 100 nM, ST 271 at 100 ,uM and PMA at 100 nM. Data 
are cpm, mean f S.E.M. (n = 3) from a single experiment representa- 
tive of 3 separate xperiments. Significantly different from ET-l alone, 
*P < 0.01. 
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ST 271 cone (uM) 
Fig. 2. Effect of ST 271 on [3H]thymidine incorporation in response 
to 24 h 1 ,uM insulin (open circles) or unstimulated controls (closed 
circles). Data are mean f S.E.M. (n = 3) from a single experiment 
representative of 3. 
22.5 + 1.1; insulin (1 PM), 31.8 ? 2.3; insulin (1 PM) 
and ET-I (10 nM), 72.6 + 3.5. 
To study the possible involvement of tyrosine kinases 
and PLD generated PA in this system we incubated cells 
with various conditions for 24 h. ST 271 (100 PM) and 
butanol (50 mM) for 24 h left cells with unchanged 
morphology and similar protein levels (e.g. control, 
22.4 + 2.4; butanol (50 mM), 21.4 + 2.2; ST 271 (100 
,uM), 23.5 ? 1.8; figures are ,ug protein per well, 
mean 4 S.E.M., n = 4). Since the effects of insulin are 
assumed to be mediated by tyrosine kinase activity then 
ST 271 will not enable separate investigation of the 
mechanism of ET-l stimulated mitogenesis. Fig. 2 
shows that insulin stimulated [3H]thymidine incorpora- 
tion was inhibited by ST 271. The IC,, over three sepa- 
rate experiments, each in triplicate, was 3.35 + 0.74,uM. 
In separate experiments we showed that ST 271 has 
similar effects on the [3H]thymidine incorporation stim- 
ulated by combined insulin and ET-l (data not shown). 
Preliminary experiments howed that insulin did not 
stimulate PLD in these cells, so butanol might be ex- 
pected to be selective for events downstream of the ET-l 
stimulation of PLD. To exclude a possible effect of 
butanol on related signal transduction mechanisms we 
preincubated [3H]inositol labelled A10 cells with 50 mM 
butanol (24 h) and showed no effect on ET-l stimula- 
tion of PLC or its augmentation by Ro 31-8220 (data 
not shown). 
Experiments were undertaken in which the ET-l 
stimulation of [3H]thymidine incorporation in the pres- 
ence of insulin was compared with and without 50 mM 
butanol. The stimulation of incorporation by insulin 
alone, expressed as -fold over basal (no insulin or ET- 1) 
was still apparent although in most cases (3 experiments 
out of 4) it was reduced (2.29 + 0.44-fold in the absence 
of butanol, and 1.96 + 0.31-fold in the presence of bu- 
tanol over the 4 experiments). However, the response to 
ET-l in the presence of insulin was lost when butanol 
was also present (Fig. 3). The results from the three 
individual experiments, expressed as a ratio of stimula- 
tion by ET-l compared to stimulation by 100 nM insu- 
lin alone, were 5.4, 2.1 and 1.49 with no butanol, and 
1.42, 0.96 and 0.52, respectively, with 50 mM butanol. 
4. DISCUSSION 
We show here that ET-l stimulates PLD in vascular 
smooth muscle A10 cells; that this activation of PLD 
involves PKC is suggested by inhibition by Ro 3 l-8220, 
and supported by stimulation of PLD by PMA. 
A role for tyrosine kinase is suggested by the inhib- 
itory effects of ST 27 1. ET- 1 has been shown to stimu- 
late tyrosine kinase by acting at ET, receptors on glom- 
erular mesangial cells [15], and ST 271 has been shown 
to potently attenuate agonist stimulated PLD, but not 
PMA stimulated PLD, by inhibition of tyrosine kinase 
activity [16]. We show here that stimulation by ET-l, 
but not PMA, in A10 cells is potently inhibited by ST 
271 with a similar IC,, to the inhibition of insulin stim- 
ulated [3H]thymidine incorporation, a tyrosine kinase 
dependent process. We report that ST 271 does not 
affect the inositol (poly)phosphate response to ET-I; 
therefore it presumably does not affect ET-l binding to 
its receptor. Nor does it act as an inhibitor of PLC, PLD 
or PKC. It seems likely therefore that the attenuation 
of the PLD response to ET-l by ST 271 is due to its 
effectiveness as a tyrosine kinase inhibitor. 
In subsequent experiments butanol (50 mM) was 
shown to leave cells intact and with functional signal 
transduction pathways even after 24 h. Butanol will 
have a selective ffect on PLD derived PA, diverting it 
to PBut. Since ET-I but not insulin (unpublished ata) 
stimulates PLD in these cells, butanol treatment pro- 
vides a strategy for selectively investigating the role of 
ET-1 stimulated PLD in the mitogenic response. Here 
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Fig. 3. Stimulation by ET-I (100 nM) in the presence of insulin (1 PM) 
of mitogenesis measured by [‘Hlthymidine incorporation in the pres- 
ence (open circles) and absence (closed circles) of 50 mM butanol 
during the 24 h incubation. Data are mean f S.E.M. (n = 3) from a 
single experiment representative of three, expressed as -fold over basal 
(no insulin or ET-l). 
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we show that butanol does abolish the ET-1 augmenta- 
tion of [3H]thymidine incorporation, while leaving a re- 
sponse to insulin intact. These results are consistent 
with the hypothesis that ET-l stimulated mitogenesis is 
mediated via PLD derived PA. 
In summary, these studies point to the conclusion 
that ET-l stimulation of PLD is dependent on both 
PKC and tyrosine kinases, and the incorporation of 
t3H]thymidine is dependent on PLD derived PA. 
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